The primary objective of this study was to assess the comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in terms of the reduction of elevated blood pressure. The primary efficacy variable was the change in sitting cuff DBP from baseline to the week 8 visit of the active treatment phase.